GSK's Anthony Rowe Puts Useful Quantum Chemistry at About 2,000 Logical Qubits Around 2030; Cleveland Clinic's Lara Jehi Tells Hospitals to Prepare Now
A pharma threshold and a hospital demonstration, reported 19 October 2026
Quentir Medicine Monitor
Evidence-based insights for quantum medicine.
Anthony Rowe, who runs research data platforms, scientific computing and AI infrastructure at GSK, gave a drug company's answer to the oldest question in quantum computing: how big must the machine be before it helps? Speaking at the City Quantum & AI Summit earlier in October, he put the tentative threshold at about 2,000 logical qubits for chemistry problems he judges beyond conventional computers, with 2030 as the horizon on current hardware roadmaps.
On the same stage, Lara Jehi, chief research information officer at Cleveland Clinic, described how her hospital, IBM and the quantum software company Algorithmiq modelled a light-activated cancer drug with a hybrid quantum-classical workflow, work that won a $2 million prize from Wellcome Leap in April 2026. Her message to hospitals was to take part now, while the machines are still being designed.
Computer Weekly reported both talks on 19 October 2026. Read together, they give a hospital research office and a pharmaceutical buyer two useful reference points: a working demonstration at today's scale, and an industry estimate of the scale at which the chemistry starts to pay. The distance between the two is the planning problem.
Rowe's figure came from his earlier pilots in quantum chemistry, protein folding and optimisation before he joined GSK. According to Computer Weekly's account of the summit, he called the threshold tentative and acknowledged that better algorithms or hardware could change it. A logical qubit is an error-corrected unit built from many physical qubits, so 2,000 logical qubits implies a machine with a far larger number of physical ones.
The more candid part of his talk concerned people. Rowe had assembled a team to explore quantum applications, and its members asked to work on AI instead. "They all came to me and said, 'We'd rather work on problems in AI right now because we can be more successful.' So fine. I mean, we can pivot," he said, adding that the industry side has to keep generating a return on investment. He also argued that the computational chemists and physicists already working in life sciences have skills that would transfer to applied quantum computing as the hardware matures.
The Minimal-Basis Run Gave T4-Lysozyme the Wrong Binding Sign: What Cleveland Clinic, RIKEN and IBM Changed to Correct It
Quentir Medicine Monitor
Evidence-based insights for quantum medicine.
On 9 September 2026 Cleveland Clinic announced that a team from Cleveland Clinic, the RIKEN Center for Computational Science and IBM had reached the finals of the 2026 ACM Gordon Bell Prize, for quantum-classical electronic-structure calculations on protein-ligand complexes of 11,608 and 12,635 atoms. Four days earlier the preprint behind that entry gained a second version, and buried in it is a result that deserves more attention than the atom count.
When the team computed the binding energy of a well-studied protein-ligand pair in a minimal basis set, the answer came out too positive, which is to say it pointed the wrong way for a ligand known to bind. Recomputing it with richer orbitals in the binding region and a tighter bath threshold together corrects the sign of the binding energy, at about ten times more in total node-hours. The revision also reports a first end-to-end wall-clock time, 62.4 hours from fragment generation to energy reconstruction, for a bound-complex ground-state run.